ArticleCurrent genomics2010
Therapeutics Based on microRNA: A New Approach for Liver Cancer.
Article in Current genomics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- Lipid Nanoparticle (LNP) Chemistry Can Endow UniqueMolecular pharmaceutics · 2022Article
- Review
- Targeted imaging and induction of apoptosis of drug-resistant hepatoma cells by miR-122-loaded graphene-InP nanocompounds.Journal of nanobiotechnology · 2017Article
- MicroRNAs as predictor markers for response to interferon treatment of chronic hepatitis C genotype-4 in Egyptian patients.PloS one · 2015Article
- Targeted delivery of chemically modified anti-miR-221 to hepatocellular carcinoma with negatively charged liposomes.International journal of nanomedicine · 2015Article
- Article
- MicroRNAs: history, biogenesis, and their evolving role in animal development and disease.Veterinary pathology · 2014Review
- Inhibiting the oncogenic mir-221 by microRNA sponge: toward microRNA-based therapeutics for hepatocellular carcinoma.Gastroenterology and hepatology from bed to bench · 2014Article
- Genetic variation in the 3'-UTR of CYP1A2, CYP2B6, CYP2D6, CYP3A4, NR1I2, and UGT2B7: potential effects on regulation by microRNA and pharmacogenomics relevance.Frontiers in genetics · 2014Article
- Evaluation of miR-122-regulated suicide gene therapy for hepatocellular carcinoma in an orthotopic mouse model.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2013Article
- In-Silico Algorithms for the Screening of Possible microRNA Binding Sites and Their Interactions.Current genomics · 2013Article
- miR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression.Journal of hepatology · 2013Article
- Illuminating microRNA Transcription from the Epigenome.Current genomics · 2013Article
- MiRNA-mediated tumor specific delivery of TRAIL reduced glioma growth.Journal of neuro-oncology · 2013Article
- MicroRNA-429 Modulates Hepatocellular Carcinoma Prognosis and Tumorigenesis.Gastroenterology research and practice · 2013Article
- Real time dynamic imaging and current targeted therapies in the war on cancer: a new paradigm.Theranostics · 2013Review
- MicroRNAs and HIV-1: complex interactions.The Journal of biological chemistry · 2012Review
- Role of microRNAs in endothelial inflammation and senescence.Molecular biology reports · 2012Review
- The Emerging Role of MicroRNAs in Hepatocellular Carcinoma.Euroasian journal of hepato-gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a serious public health hazard. Polygenes involvement, accumulation of genetic and epigenetic changes and immune response of viral vector during gene therapy have resulted in the high mortality rate without marked change. To provide a safeguard for gene therapy and the feasibility for a clinical application, efforts have been focused predominantly upon constructing liver-targeted vector recently. MicroRNAs (miRNAs), a class of short endogenous RNAs, regulate the gene expression at the post-transcriptional level through imperfect base pairing with the 3'-untranslated region of target mRNAs. miRNAs, especially the liver-specific miRNA: miR-122, have multiple functions in liver development and abnormal expression of miRNAs could lead to liver diseases. Altered miRNA expressions have been observed in HCCs, viral hepatitis and hepatic fibrosis. The different expression profiles of miRNAs in HCC suggest that miRNAs may serve as either novel potential targets acting directly as oncogenes or therapeutic molecules working as tumor suppressor genes. Moreover, the abundance in general and liver specificity in particular, all together make them attractive to be considered as elements for hepatic specific targeting viral vector. This review describes recent progress in miRNA investigation on liver associated for better understanding the relationship between miRNA and liver cancer in order to raise prospects for therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.